Influence of Amine Substituents on 5-HT2A versus 5-HT2C Binding of Phenylalkyl- and Indolylalkylamines

Click to copy article linkArticle link copied!

This article is cited by 52 publications.

1. Richard A. Glennon, Małgorzata Dukat. 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents – A Review. ACS Pharmacology & Translational Science 2024, 7 (6) , 1722-1745. https://doi.org/10.1021/acsptsci.4c00157
2. Emil M. Ro̷rsted, Anders A. Jensen, Gints Smits, Karla Frydenvang, Jesper L. Kristensen. Discovery and Structure–Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists. Journal of Medicinal Chemistry 2024, 67 (9) , 7224-7244. https://doi.org/10.1021/acs.jmedchem.4c00082
3. Breno A. Soares, Thirumal Yempala, Darío Martínez-Afani, Williams Acevedo-Fuentes, José Brea, María Isabel Loza, Marta Cimadevila, Bruce K. Cassels. Effect of Bulky N-Dibenzofuranylmethyl Substitution on the 5-HT2 Receptor Affinity and Efficacy of a Psychedelic Phenethylamine. ACS Chemical Neuroscience 2024, 15 (3) , 608-616. https://doi.org/10.1021/acschemneuro.3c00639
4. Alexander M. Sherwood, Elise K. Burkhartzmeyer, Samuel E. Williamson, Michael H. Baumann, Grant C. Glatfelter. Psychedelic-like Activity of Norpsilocin Analogues. ACS Chemical Neuroscience 2024, 15 (2) , 315-327. https://doi.org/10.1021/acschemneuro.3c00610
5. Wenwen Duan, Dongmei Cao, Sheng Wang, Jianjun Cheng. Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants. Chemical Reviews 2024, 124 (1) , 124-163. https://doi.org/10.1021/acs.chemrev.3c00375
6. Christian B. M. Poulie, Anders A. Jensen, Adam L. Halberstadt, Jesper L. Kristensen. DARK Classics in Chemical Neuroscience: NBOMes. ACS Chemical Neuroscience 2020, 11 (23) , 3860-3869. https://doi.org/10.1021/acschemneuro.9b00528
7. Emil Marcher-Rørsted, Adam L. Halberstadt, Adam K. Klein, Muhammad Chatha, Simon Jademyr, Anders A. Jensen, Jesper L. Kristensen. Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists. ACS Chemical Neuroscience 2020, 11 (9) , 1238-1244. https://doi.org/10.1021/acschemneuro.0c00129
8. David E. Nichols, M. Flori Sassano, Adam L. Halberstadt, Landon M. Klein, Simon D. Brandt, Simon P. Elliott, and Wolfgang J. Fiedler . N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues. ACS Chemical Neuroscience 2015, 6 (7) , 1165-1175. https://doi.org/10.1021/cn500292d
9. Scott P. Runyon, Philip D. Mosier, Bryan L. Roth, Richard A. Glennon and Richard B. Westkaemper . Potential Modes of Interaction of 9-Aminomethyl-9,10-dihydroanthracene (AMDA) Derivatives with the 5-HT2A Receptor: A Ligand Structure-Affinity Relationship, Receptor Mutagenesis and Receptor Modeling Investigation. Journal of Medicinal Chemistry 2008, 51 (21) , 6808-6828. https://doi.org/10.1021/jm800771x
10. Aaron P. Monte,, Danuta Marona-Lewicka,, Matthew A. Parker,, David B. Wainscott,, David L. Nelson, and, David E. Nichols. Dihydrobenzofuran Analogues of Hallucinogens. 3. Models of 4-Substituted (2,5-Dimethoxyphenyl)alkylamine Derivatives with Rigidified Methoxy Groups. Journal of Medicinal Chemistry 1996, 39 (15) , 2953-2961. https://doi.org/10.1021/jm960199j
11. Michael Noback, Johnny A. Kenton, Adam K. Klein, Zoë A. Hughes, Andrew C. Kruegel, Yasmin Schmid, Adam L. Halberstadt, Jared W. Young. Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice. Neuropharmacology 2025, 268 , 110334. https://doi.org/10.1016/j.neuropharm.2025.110334
12. Romain Pelletier, Thomas Gicquel, Julien Carvelli, Pierre Balaz, Anne-Laure Pelissier-Alicot, Isabelle Morel, Charline Bottinelli, Caroline Solas, Brendan Le Daré, Nicolas Fabresse. Severe 25E-NBOH intoxication associated with MDPHP intake: a case report, metabolism study, and literature review. International Journal of Legal Medicine 2024, 138 (3) , 815-822. https://doi.org/10.1007/s00414-023-03151-6
13. Ryan Gallagher, Maddison G. McLaughlin, Karen Blakey, Urs D. Wermuth, Sue Boyd, Jenny McGowan. N , N ‐Diformylmescaline: A novel analogue of mescaline detected in Queensland. Drug Testing and Analysis 2023, 15 (2) , 204-212. https://doi.org/10.1002/dta.3390
14. Scott R. Walker, Glenn A. Pullella, Matthew J. Piggott, Peter J. Duggan, . Introduction to the chemistry and pharmacology of psychedelic drugs. Australian Journal of Chemistry 2023, 76 (5) , 236-257. https://doi.org/10.1071/CH23050
15. Johannes T. Reckweg, Malin V. Uthaug, Attila Szabo, Alan K. Davis, Rafael Lancelotta, Natasha L. Mason, Johannes G. Ramaekers. The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT). Journal of Neurochemistry 2022, 162 (1) , 128-146. https://doi.org/10.1111/jnc.15587
16. Agata Hogendorf, Adam S. Hogendorf, Rafał Kurczab, Grzegorz Satała, Bernadeta Szewczyk, Paulina Cieślik, Gniewomir Latacz, Jadwiga Handzlik, Tomasz Lenda, Katarzyna Kaczorowska, Jakub Staroń, Ryszard Bugno, Beata Duszyńska, Andrzej J. Bojarski. N-Skatyltryptamines—Dual 5-HT6R/D2R Ligands with Antipsychotic and Procognitive Potential. Molecules 2021, 26 (15) , 4605. https://doi.org/10.3390/molecules26154605
17. Laura Clancy, Morgan Philp, Ronald Shimmon, Shanlin Fu. Development and validation of a color spot test method for the presumptive detection of 25‐NBOMe compounds. Drug Testing and Analysis 2021, 13 (5) , 929-943. https://doi.org/10.1002/dta.2905
18. Paul Cumming, Milan Scheidegger, Dario Dornbierer, Mikael Palner, Boris B. Quednow, Chantal Martin-Soelch. Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. Molecules 2021, 26 (9) , 2451. https://doi.org/10.3390/molecules26092451
19. Anna Šuláková, Jitka Nykodemová, Petr Palivec, Radek Jurok, Silvie Rimpelová, Tereza Leonhardt, Klára Šíchová, Tomáš Páleníček, Martin Kuchař. 25CN-NBOMe Metabolites in Rat Urine, Human Liver Microsomes and C. elegans—Structure Determination and Synthesis of the Most Abundant Metabolites. Metabolites 2021, 11 (4) , 212. https://doi.org/10.3390/metabo11040212
20. Nicholas M. Barnes, Gerard P. Ahern, Carine Becamel, Joël Bockaert, Michael Camilleri, Severine Chaumont-Dubel, Sylvie Claeysen, Kathryn A. Cunningham, Kevin C. Fone, Michael Gershon, Giuseppe Di Giovanni, Nathalie M. Goodfellow, Adam L. Halberstadt, Rachel M. Hartley, Ghérici Hassaine, Katharine Herrick-Davis, Ruud Hovius, Enza Lacivita, Evelyn K. Lambe, Marcello Leopoldo, Finn Olav Levy, Sarah C.R. Lummis, Philippe Marin, Luc Maroteaux, Andrew C. McCreary, David L. Nelson, John F. Neumaier, Adrian Newman-Tancredi, Hugues Nury, Alexander Roberts, Bryan L. Roth, Anne Roumier, Gareth J. Sanger, Milt Teitler, Trevor Sharp, Carlos M. Villalón, Horst Vogel, Stephanie W. Watts, Daniel Hoyer. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews 2021, 73 (1) , 310-520. https://doi.org/10.1124/pr.118.015552
21. Olga V. Kupriyanova, Vadim A. Shevyrin, Yuri M. Shafran, Albert T. Lebedev, Vasili A. Milyukov, Vladimir L. Rusinov. Synthesis and determination of analytical characteristics and differentiation of positional isomers in the series of N ‐(2‐methoxybenzyl)‐2‐(dimethoxyphenyl)ethanamine using chromatography–mass spectrometry. Drug Testing and Analysis 2020, 12 (8) , 1154-1170. https://doi.org/10.1002/dta.2859
22. Karolina E. Kolaczynska, Dino Luethi, Daniel Trachsel, Marius C. Hoener, Matthias E. Liechti. Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines. Frontiers in Pharmacology 2019, 10 https://doi.org/10.3389/fphar.2019.01423
23. Joshua S. Elmore, Ann M. Decker, Agnieszka Sulima, Kenner C. Rice, John S. Partilla, Bruce E. Blough, Michael H. Baumann. Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology 2018, 142 , 240-250. https://doi.org/10.1016/j.neuropharm.2018.02.033
24. Katharina Elisabeth Grafinger, Katja Stahl, Andreas Wilke, Stefan König, Wolfgang Weinmann. In vitro phase I metabolism of three phenethylamines 25D‐NBOMe, 25E‐NBOMe and 25N‐NBOMe using microsomal and microbial models. Drug Testing and Analysis 2018, 10 (10) , 1607-1626. https://doi.org/10.1002/dta.2446
25. Laura Hondebrink, Anne Zwartsen, Remco H.S. Westerink. Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?. Pharmacology & Therapeutics 2018, 182 , 193-224. https://doi.org/10.1016/j.pharmthera.2017.10.022
26. Daniel Pasin, Adam Cawley, Sergei Bidny, Shanlin Fu. Characterization of hallucinogenic phenethylamines using high‐resolution mass spectrometry for non‐targeted screening purposes. Drug Testing and Analysis 2017, 9 (10) , 1620-1629. https://doi.org/10.1002/dta.2171
27. Adam L. Halberstadt. Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens. 2017, 283-311. https://doi.org/10.1007/7854_2016_64
28. Adam L. Halberstadt, Mark A. Geyer. Effect of Hallucinogens on Unconditioned Behavior. 2016, 159-199. https://doi.org/10.1007/7854_2016_466
29. Daniel Trachsel. Fluorine in psychedelic phenethylamines. Drug Testing and Analysis 2012, 4 (7-8) , 577-590. https://doi.org/10.1002/dta.413
30. Adam L. Halberstadt, David E. Nichols, Mark A. Geyer. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology 2012, 221 (4) , 709-718. https://doi.org/10.1007/s00213-011-2616-6
31. Adam L. Halberstadt, Mark A. Geyer. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 2011, 61 (3) , 364-381. https://doi.org/10.1016/j.neuropharm.2011.01.017
32. Nicolas Renault, Arnaud Gohier, Philippe Chavatte, Amaury Farce. Novel structural insights for drug design of selective 5-HT2C inverse agonists from a ligand-biased receptor model. European Journal of Medicinal Chemistry 2010, 45 (11) , 5086-5099. https://doi.org/10.1016/j.ejmech.2010.08.018
33. Manolo Casagrande, Nicoletta Basilico, Chiara Rusconi, Donatella Taramelli, Anna Sparatore. Synthesis, antimalarial activity, and cellular toxicity of new arylpyrrolylaminoquinolines. Bioorganic & Medicinal Chemistry 2010, 18 (18) , 6625-6633. https://doi.org/10.1016/j.bmc.2010.08.001
34. Daniel Trachsel, David E. Nichols, Stephanie Kidd, Marcel Hadorn, Franz Baumberger. 4‐Aryl‐Substituted 2,5‐Dimethoxyphenethylamines: Synthesis and Serotonin 5‐HT 2A Receptor Affinities. Chemistry & Biodiversity 2009, 6 (5) , 692-704. https://doi.org/10.1002/cbdv.200800235
35. Antoni R. Blaazer, Pieter Smid, Chris G. Kruse. Structure–Activity Relationships of Phenylalkylamines as Agonist Ligands for 5‐HT 2A Receptors. ChemMedChem 2008, 3 (9) , 1299-1309. https://doi.org/10.1002/cmdc.200800133
36. Manolo Casagrande, Nicoletta Basilico, Silvia Parapini, Sergio Romeo, Donatella Taramelli, Anna Sparatore. Novel amodiaquine congeners as potent antimalarial agents. Bioorganic & Medicinal Chemistry 2008, 16 (14) , 6813-6823. https://doi.org/10.1016/j.bmc.2008.05.068
37. Michael R. Braden, Jason C. Parrish, John C. Naylor, David E. Nichols. Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists. Molecular Pharmacology 2006, 70 (6) , 1956-1964. https://doi.org/10.1124/mol.106.028720
38. Diego Bustamante, Gabriela Díaz-Véliz, Carlos Paeile, Gerald Zapata-Torres, Bruce K. Cassels. Analgesic and behavioral effects of amphetamine enantiomers, p-methoxyamphetamine and n-alkyl-p-methoxyamphetamine derivatives. Pharmacology Biochemistry and Behavior 2004, 79 (2) , 199-212. https://doi.org/10.1016/j.pbb.2004.06.017
39. J. Schmaljohann, A. Becherer, K. Kletter, D. Gündisch. Radiosynthesis and in vitro evaluation of the 5HT 2 receptor ligand [N- 11 C-methyl]-1-[2,5-dimethoxy-4-iodophenyl]-2-methylaminopropane for PET. Radiochimica Acta 2004, 92 (4-6) , 345-348. https://doi.org/10.1524/ract.92.4.345.35592
40. Daniel Trachsel. Synthesis of Novel (Phenylalkyl)amines for the Investigation of StructureActivity Relationships, Part 3. Helvetica Chimica Acta 2003, 86 (8) , 2754-2759. https://doi.org/10.1002/hlca.200390224
41. Daniel Trachsel. Synthese von neuen (Phenylalkyl)aminen zur Untersuchung von Struktur–Aktivitätsbeziehungen. Mitteilung 2. Helvetica Chimica Acta 2003, 86 (7) , 2610-2619. https://doi.org/10.1002/hlca.200390210
42. Antje Harms, Ernst Ulmer, Karl‐Artur Kovar. Synthesis and 5‐HT 2A Radioligand Receptor Binding Assays of DOMCl and DOMOM, Two Novel 5‐HT 2A Receptor Ligands. Archiv der Pharmazie 2003, 336 (3) , 155-158. https://doi.org/10.1002/ardp.200390014
43. Ol'ga N Zefirova, Nikolai S Zefirov. Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors. Russian Chemical Reviews 2001, 70 (4) , 333-355. https://doi.org/10.1070/RC2001v070n04ABEH000654
44. Scott P. Runyon, Jason E. Savage, Mohamed Taroua, Bryan L. Roth, Richard A. Glennon, Richard B. Westkaemper. Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene. Bioorganic & Medicinal Chemistry Letters 2001, 11 (5) , 655-658. https://doi.org/10.1016/S0960-894X(01)00023-3
45. Masanori SOMEI, Sakiko TERANISHI, Koji YAMADA, Fumio YAMADA. The Chemistry of Indoles. CVII. A Novel Synthesis of 3,4,5,6-Tetrahydro-7-hydroxy-1H-azepino[5,4,3-cd]indoles and a New Finding on Pictet-Spengler Reaction.. Chemical and Pharmaceutical Bulletin 2001, 49 (9) , 1159-1165. https://doi.org/10.1248/cpb.49.1159
46. Michael C. McBride. Bufotenine: Toward an Understanding of Possible Psychoactive Mechanisms. Journal of Psychoactive Drugs 2000, 32 (3) , 321-331. https://doi.org/10.1080/02791072.2000.10400456
47. Antje Harms, Daniela Gündisch, Christa E. Müller, Karl-Artur Kovar. Development Assay for of a 5-Hydroxytryptamine2A Receptor Binding High Throughput Screening Using 96-Well Microfilter Plates. SLAS Discovery 2000, 5 (4) , 269-277. https://doi.org/10.1177/108705710000500410
48. Milton A. Torres, C. Rezende, Bruce K. Cassels. α1-Adrenergic and 5-HT2-Serotonergic Effects of Some β-Alkoxy-β-phenylethylamines on Isolated Rat Thoracic Aorta. General Pharmacology: The Vascular System 1998, 31 (1) , 51-54. https://doi.org/10.1016/S0306-3623(97)00421-7
49. Kouichiro Minami, Makiko Minami, R. Adron Harris. Inhibition of 5-Hydroxytryptamine Type 2A Receptor-Induced Currents by n-Alcohols and Anesthetics. The Journal of Pharmacology and Experimental Therapeutics 1997, 281 (3) , 1136-1143. https://doi.org/10.1016/S0022-3565(24)36721-7
50. . 5-HT2A, 5-HT2B and 5-HT2C receptor ligands. 1997, 161-197. https://doi.org/10.1016/S0165-7208(97)80013-X
51. . The 5-HT2-type receptor family. 1997, 199-214. https://doi.org/10.1016/S0165-7208(97)80014-1
52. Kurt Kristiansen, Svein G. Dahl. Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT2C receptor interactions. European Journal of Pharmacology 1996, 306 (1-3) , 195-210. https://doi.org/10.1016/0014-2999(96)00180-X